AP NEWS

The Sickle-Cell Anemia Therapeutics Market in the United States: 2018 to 2022 - Led by Bristol-Myers Squibb, Emmaus Medical and Medunik USA - ResearchAndMarkets.com

February 13, 2019

DUBLIN--(BUSINESS WIRE)--Feb 13, 2019--The “Sickle-Cell Anemia Therapeutics Market in the US 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The sickle-cell anemia therapeutics market in the US will register a CAGR of over 15% by 2022.

Sickle-cell anemia treatment is associated with high cost medications in the US

To reduce the treatment burden on the patients, several companies and government organizations are offering reimbursement for the treatment. Several stakeholders are offering partnerships to work with state and local policyholders and the payer group to ensure the payment and reimbursement are in place so that the providers can be supported to advance access to quality care.

Recent product approvals for sickle-cell anemia

Due to fewer product availability in the US for the treatment of sickle-cell anemia, hence these recently approved products drive the market over the forecast period.

Limited number of approved drugs

The availability of very limited approved therapies for the treatment of sickle-cell anemia id the US is expected to hamper the growth of the market during our forecast period.

Competitive Landscape

The sickle-cell anemia therapeutics market in the US is highly concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Key Players

Bristol-Myers Squibb Emmaus Medical Medunik USA

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry

PART 07: MARKET SEGMENTATION BY THERAPY

Comparison by therapy Hydroxyurea - Market size and forecast 2017-2022 L-glutamine therapy - Market size and forecast 2017-2022 Market opportunity by therapy

PART 08: CUSTOMER LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

Introduction of gene therapy Strategic alliances Orphan drug designations for sickle-cell anemia

PART 12: VENDOR LANDSCAPE

Overview Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb Emmaus Medical Medunik USA

For more information about this report visit https://www.researchandmarkets.com/research/rmbznc/the_sicklecell?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190213005442/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD: UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL PHYSICAL THERAPY

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/13/2019 08:56 AM/DISC: 02/13/2019 08:56 AM

http://www.businesswire.com/news/home/20190213005442/en

AP RADIO
Update hourly